Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced
Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
Patient must have historically documented, incurable, locally advanced or metastatic cancer
that are refractory to standard therapies of one of the following types:
1. Triple negative breast cancer
2. Epithelial ovarian cancer
3. Non-small cell lung cancer
4. Gastric adenocarcinoma
5. Small cell lung cancer
6. Urothelial carcinoma